1 Supplementary Text:

2 Details of mechanistic model

Each infected host (who developed symptoms) was assumed to progress through latent (*E*),
presymptomatic infectious (*P*) and symptomatic infectious (*I*) stages. We denote the
infectiousness of hosts in the *P* and *I* stages by β_P and β_I, respectively, and define the ratio
α_P = β_P/β_I. The duration of each stage, denoted y_{E/P/I}, was assumed to be gamma
distributed:

8
$$y_E \sim \text{Gamma}(k_E, 1/(k_{inc}\gamma)),$$

9
$$y_P \sim \text{Gamma}(k_P, 1/(k_{inc}\gamma)),$$

10
$$y_I \sim \text{Gamma}(k_I, 1/(k_I \mu)),$$

where we write X ~ Gamma(a, b) for a gamma distributed random variable with shape
parameter a and scale parameter b. We assumed that k_E + k_P = k_{inc}, so that the incubation
period, τ_{inc} = y_E + y_P, was gamma distributed, with

14
$$\tau_{inc} \sim \text{Gamma}(k_{inc}, 1/(k_{inc}\gamma))$$

15 Here, the parameters k_{inc} and $1/\gamma$ (which represent the shape parameter of the incubation 16 period distribution and the reciprocal of the mean incubation period, respectively) were fixed 17 in order to obtain the specified incubation period distribution (the exact values that we 18 assumed are given in Table S1).

19

20 For simplicity, we assumed that $k_I = 1$, so the symptomatic infectious period was

21 exponentially distributed. The parameters k_E (the shape parameter of the latent (E) period

22 distribution), $1/\mu$ (the mean symptomatic infectious (I) period) and α_P (the ratio between the

transmission rates of hosts in the *P* and *I* stages) were estimated when we fitted the model to

the household transmission data.

Hosts who remained asymptomatic throughout infection were assumed to follow the same E/P/I stages, although in this case the distinction between the *P* and *I* stages has no epidemiological meaning. Stage durations, as well as the value of α_P , were assumed to be identical for entirely asymptomatic hosts and those who developed symptoms, so that the generation time distribution was the same for all hosts.

31

32 Conditional infectiousness

33 For a host who develops symptoms, conditional on incubation period τ_{inc} , the expected

34 infectiousness at time since infection τ is [1]

35
$$\beta(\tau \mid \tau_{inc}) = \begin{cases} \alpha_P C(\beta_0/n)(1 - F_{Beta}(1 - \tau/\tau_{inc}; k_P, k_E)), & 0 < \tau < \tau_{inc}, \\ C(\beta_0/n)(1 - F_I(\tau - \tau_{inc})), & \tau > \tau_{inc}. \end{cases}$$

Here, β₀ is the overall infectiousness parameter (see Methods in the main text), n is the
household size, F_I(y) is the cumulative distribution of the duration of the *I* stage,
F_{Beta}(x; a, b) is the cumulative distribution of a beta distributed random variable with shape
parameters a and b, and

40
$$C = \frac{k_{inc}\gamma\mu}{\alpha_P k_P \mu + k_{inc}\gamma}.$$

41

42 The cumulative conditional infectiousness can therefore be calculated to be

$$43 \qquad B(\tau \mid \tau_{inc}) = \int_{0}^{\tau} \beta(\tilde{\tau} \mid \tau_{inc}) d\tilde{\tau}$$

$$44 \qquad = \begin{cases} (\tau - \tau_{inc})\beta(\tau \mid \tau_{inc}) + \frac{\alpha_{P}C\beta_{0}}{n} \Big[\frac{k_{p}\tau_{inc}}{k_{inc}} \big(1 - F_{Beta}(1 - \tau/\tau_{inc}; k_{P} + 1, k_{E}) \big) \Big], \qquad 0 \le \tau < \tau_{inc}, \\ (\tau - \tau_{inc})\beta(\tau \mid \tau_{inc}) + \frac{C\beta_{0}}{n} \Big[\frac{\alpha k_{p}\tau_{inc}}{k_{inc}} + \frac{1}{\mu}F_{Gamma} \Big(\tau - \tau_{inc}; k_{I} + 1, \frac{1}{k_{I}\mu} \Big) \Big], \qquad \tau \ge \tau_{inc}, \end{cases}$$

45 where $F_{Gamma}(x; a, b)$ is the cumulative distribution of a gamma distributed random variable 46 with shape parameter *a* and scale parameter *b*. The total force of infection on each household 47 member (over the course of infection) is then

$$B(\infty \mid \tau_{inc}) = \frac{\beta_0}{n} \left(\frac{\alpha k_P \gamma \mu \tau_{inc} + k_{inc} \gamma}{\alpha k_P \mu + k_{inc} \gamma} \right).$$

The mean of this expression over the incubation period distribution is then β_0/n .

49

50 51 For hosts who remained asymptomatic throughout infection, conditional on the combined 52 duration of the *E* and *P* stages, $\tau_{inc} = y_E + y_P$, the infectiousness, $\beta(\tau | \tau_{inc})$, was given by 53 α_A times the corresponding expression for those who developed symptoms. We note that in 54 this case, τ_{inc} has no epidemiological interpretation, but this conditional infectiousness was 55 useful when fitting parameters (see "Parameter fitting" below).

56

57 *Generation time distribution*

58 The generation time, τ_{gen} , can be written as

59
$$\tau_{gen} = y_E + y^*$$

60 where y_E is the length of the latent (*E*) stage, and y^* is the time from the start of the

61 presymptomatic infectious (*P*) stage to the transmission occurring. As shown in [1], y^* has 62 density

63
$$f^*(y^*) = C\left(\alpha_P(1 - F_P(y^*)) + \int_0^{y^*} (1 - F_I(y^* - y_P))f_P(y_P)dy_P\right)$$

64 Using this density, it can be shown that the moments of this distribution are

65
$$E[(y^*)^m] = \frac{C}{m+1} (\alpha_P E[y_P^{m+1}] + E[(y_P + y_I)^{m+1} - y_P^{m+1}]).$$

66 In particular, we have

67
$$E[y^*] = \frac{C}{2} (\alpha_P E[y_P^2] + 2E[y_P]E[y_I] + E[y_I^2]),$$

68
$$\operatorname{Var}[y^*] = \frac{C}{3} (\alpha_P E[y_P^3] + 3E[y_P^2]E[y_I] + 3E[y_P]E[y_I^2] + E[y_I^2]) - (E[y^*])^2.$$

69 Note that for a gamma distributed random variable, $X \sim \text{Gamma}(a, b)$, we have

70
$$E[X^m] = \frac{\Gamma(a+m)}{\Gamma(a)} b^m = a(a+1) \dots (a+(m-1))b^m$$

Therefore, for gamma distributed stage durations, explicit expressions can be obtained for the
mean and variance of the generation time distribution,

73
$$E[\tau_{gen}] = E[y_E] + E[y^*],$$

74
$$\operatorname{Var}[\tau_{gen}] = \operatorname{Var}[y_E] + \operatorname{Var}[y^*]$$

75 since y_E and y^* are assumed to be independent.

76

77 Proportion of presymptomatic transmissions

Among infectors who develop symptoms, the proportion of transmissions occurring prior to
symptom onset is given by [1]

80
$$q_P = \frac{\left(\frac{\beta_P k_P}{k_{inc}\gamma}\right)}{\left(\frac{\beta_P k_P}{k_{inc}\gamma} + \frac{\beta_I}{\mu}\right)} = \frac{\alpha_P k_P \mu}{\alpha_P k_P \mu + k_{inc}\gamma}.$$

81

82 Parameter fitting

83 The vector of model parameters,

84

 $\theta = (k_E/k_{inc}, 1/\mu, \alpha_P, \beta_0),$

85 was estimated by fitting the mechanistic model to the household transmission data.

86

We assumed independent prior distributions for each entry of θ . Lognormal priors were assumed for $1/\mu$, α_P and β_0 . Since α_P represents the ratio between the transmission rate of hosts in the *P* and *I* stages, a prior with median 0 was used to ensure equal prior probabilities of values above and below 1. This prior was also chosen to limit the prior probability of extreme values, with a prior 95% credible interval of [0.2,5]. A beta prior was used for k_E/k_{inc} (which was constrained to lie between 0 and 1), and was chosen to restrict the prior probability of values very close to either 0 or 1. The exact priors we used are given in TableS3.

95

A slightly amended version of the parameter fitting algorithm described in the main text for
the independent transmission and symptoms model was used. In particular, we augmented the
observed data with:

99 i. The infection time, t_i , of each infected host.

100 ii. The time, $t_{s,j}$, at which each infected host transitioned from the P to I stage.

101 Note that for hosts who developed symptoms, the time of entry into the *I* stage corresponds to

the symptom onset time. The data were also augmented with this transition time for entirely

103 asymptomatic infected hosts because the conditional infectiousness, $\beta(\tau \mid t_{s,j} - t_j)$, was

104 relatively easy to calculate compared to $\beta(\tau)$.

105

106 In each step of the chain, we carried out (in turn) one of the following:

107 1. Propose new values for the vector of model parameters, θ , using a multivariate 108 normal proposal distribution (around the value of θ in the previous step of the 109 chain; a correlation of 0.5 was used between the proposal distributions of 110 k_E/k_{inc} and α_P , and between those of $1/\mu$ and α_P). Accept the proposed 111 parameters, θ_{prop} , with probability

112
$$\min\left(\frac{L(\theta_{prop}; \boldsymbol{t})\pi(\theta_{prop})}{L(\theta_{old}; \boldsymbol{t})\pi(\theta_{old})}, 1\right),$$

where θ_{old} denotes the vector of parameter values from the previous step of
the chain, and where the augmented data, *t*, remain unchanged in this step.
Propose new values for the precise symptom onset times of each symptomatic
infected host, using independent uniform proposal distributions (within the

117 day of symptom of onset for each host). For each household, m, accept the 118 proposed augmented data, $t_{prop}^{(m)}$, from that household with probability

119
$$\min\left(\frac{L^{(m)}\left(\theta; \boldsymbol{t}_{prop}^{(m)}\right)}{L^{(m)}\left(\theta; \boldsymbol{t}_{old}^{(m)}\right)}, 1\right),$$

where $t_{old}^{(m)}$ denotes the corresponding augmented data from the previous step 120 of the chain, and where the model parameters, θ , remain unchanged in this 121 step (i.e., proposed times are accepted/rejected independently for each 122 123 household, according to the likelihood contribution from that household). 3. Propose new values for the infection time of one randomly chosen infected 124 host in each household (either symptomatic or asymptomatic), using 125 independent normal proposal distributions (around the equivalent times in the 126 previous step of the chain). For each household, m, accept the proposed 127 augmented data, $t_{prop}^{(m)}$, from that household with probability 128

129
$$\min\left(\frac{L^{(m)}\left(\theta; \boldsymbol{t}_{prop}^{(m)}\right)}{L^{(m)}\left(\theta; \boldsymbol{t}_{old}^{(m)}\right)}, 1\right).$$

1304. Propose new values for both the infection time, t, and the time of the start of131the I stage, t_s , holding $t_s - t$ constant, for one randomly chosen asymptomatic132infected host in each household (in households where there was at least one),133using independent normal proposal distributions (around the equivalent times134in the previous step of the chain). For each household, m, accept the proposed135augmented data, $t_{prop}^{(m)}$, from that household with probability

136
$$\min\left(\frac{L^{(m)}\left(\theta; \boldsymbol{t}_{prop}^{(m)}\right)}{L^{(m)}\left(\theta; \boldsymbol{t}_{old}^{(m)}\right)}, 1\right).$$

- 138 <u>Relationship between generation time, TOST and serial interval</u>
- 139 Here, we consider a randomly chosen infector-infectee pair (in which both the infector and

140 the infectee develop symptoms) within a large, well-mixed population. In that setting, the

- 141 observed distribution of generation times is equal to the normalised infectiousness profile,
- 142 which will not be true within a household (cf. Figure 1 and Figure S4). We define:

143
$$\tau_{inc,1} = (incubation period of the infector),$$

144
$$\tau_{inc,2} = (incubation period of the infectee),$$

145 $\tau_{gen} = (\text{generation time}),$

146
$$x_{tost} = (time from onset of symptoms (of infector) to transmission (TOST)),$$

147
$$x_{ser} = (serial interval),$$

148 where we use τ for time intervals relative to the time of infection and x for those relative to 149 the time of symptom onset. We denote the probability density functions of these time periods 150 by $f_{inc,1}$, $f_{inc,2}$, f_{gen} , f_{tost} and f_{ser} , respectively. Note that we have

151
$$x_{tost} = \tau_{gen} - \tau_{inc,1},$$

152 and

$$x_{ser} = x_{tost} + \tau_{inc,2}$$

154 so that

155
$$x_{ser} = \tau_{gen} + \tau_{inc,2} - \tau_{inc,1}.$$

- 156
- 157 In the independent transmission and symptoms model, τ_{gen} and $\tau_{inc,1}$ are assumed to be
- independent, and the incubation periods of the infector and infectee are assumed to be drawn
- 159 independently from the population incubation period distribution, $f_{inc} = f_{inc,1} = f_{inc,2}$.

160 Therefore, the TOST distribution is given by the convolution

161
$$f_{tost}(x_{tost}) = \int_0^\infty f_{gen}(x_{tost} + \tau) f_{inc}(\tau) \,\mathrm{d}\tau. \tag{1}$$

162 We also assume that x_{tost} and $\tau_{inc,2}$ are independent, so the serial interval distribution can be 163 calculated from the TOST distribution as

164
$$f_{ser}(x_{ser}) = \int_0^\infty f_{tost}(x_{ser} - \tau) f_{inc}(\tau) \,\mathrm{d}\tau. \tag{2}$$

165 Note that

166
$$E[x_{ser}] = E[\tau_{gen}] + E[\tau_{inc,2}] - E[\tau_{inc,1}] = E[\tau_{gen}],$$

167 i.e., the generation time and serial interval distributions have the same mean.

168

For the mechanistic model, we still have $f_{inc,2} = f_{inc}$, and the serial interval distribution can be calculated from the TOST distribution using equation (2). On the other hand, τ_{gen} and $\tau_{inc,1}$ are not independent, so equation (1) connecting the TOST and generation time distributions for the independent transmission and symptoms model does not hold for the mechanistic model. As shown in [1], the TOST distribution for the mechanistic model is, instead, given by

175
$$f_{tost}(x_{tost}) = \begin{cases} \alpha_P C(1 - F_P(-x_{tost})), & x_{tost} < 0, \\ C(1 - F_I(x_{tost})), & x_{tost} \ge 0. \end{cases}$$

176

Further, under the mechanistic model, the expected number of presymptomatic transmissions generated by an infected host is dependent on their incubation period. As a result, the infector's incubation period does not follow the same distribution as that of the infectee. In particular, by Bayes' theorem, we have

181
$$f_{inc,1}(\tau_{inc,1}) = p(\tau_{inc,1} \mid 1 \to 2) = \frac{p(1 \to 2 \mid \tau_{inc,1}) f_{inc}(\tau_{inc,1})}{p(1 \to 2)}$$

where we write $1 \rightarrow 2$ to denote the occurrence of the transmission from the infector to the infectee. Because we are here considering a large population, the probability of the 184 transmission occurring is proportional to the overall infectiousness of the infector (integrated 185 over the course of infection), $B(\infty)$, so we have

186
$$f_{inc,1}(\tau_{inc,1}) = \frac{B(\infty \mid \tau_{inc})f_{inc}(\tau_{inc,1})}{B(\infty)} = \left(\frac{\alpha_P k_P \gamma \mu \tau_{inc,1} + k_{inc} \gamma}{\alpha_P k_P \mu + k_{inc} \gamma}\right) f_{inc}(\tau_{inc,1}).$$

187 The expected incubation period of the infector is then

188
$$E[\tau_{inc,1}] = \frac{1}{\gamma} + \frac{\alpha_P k_P \mu}{k_{inc} \gamma (\alpha_P k_P \mu + k_{inc} \gamma)} = E[\tau_{inc,2}] + \frac{q_P}{k_{inc} \gamma}$$

189 where q_P is the proportion of transmissions occurring prior to symptom onset.

190

191 As a result of the above, the expected values of the generation time and serial interval in the

192 mechanistic model are not equal. Instead, we have

193
$$E[x_{ser}] = E[\tau_{gen}] - \frac{q_P}{k_{inc}\gamma}.$$

194 Under the values of k_{inc} and γ that we assumed (Table S1), this gives a mean generation time

195 that is approximately $(1.6 \times q_P)$ days longer than the mean serial interval.

197 Supplementary Figures:





199 Figure S1. Posterior distributions for the independent transmission and symptoms model. Prior

200 distributions (black dotted lines), posterior distributions (blue bars), and posterior means (vertical red dotted

201 lines) for fitted parameters in the independent transmission and symptoms model. A. Mean generation time. B.

202 Standard deviation of generation times. C. Overall infectiousness, β_0 .



204

205 Figure S2. Posterior distributions for the mechanistic model. Prior distributions (black dotted lines), 206 posterior distributions (blue bars), and posterior means (vertical red dotted lines) for fitted parameters in the 207 mechanistic model. A. Ratio of mean durations of the latent (E) and incubation (E+P) periods, k_E/k_{inc} . B. 208 Mean symptomatic infectious (I) period, $1/\mu$. C. Ratio of transmission rates in the P and I stages, α_P . D. Overall 209 infectiousness, β_0 .









Figure S4. Generation times within study households. Violin plots indicating posterior distributions of the
mean (A) and standard deviation (B) of realised generation times in the study households, and the proportion of
transmissions occurring prior to symptom onset (C), for the independent transmission and symptoms model
(blue) and mechanistic model (red).



227 Figure S5. Number of study households and household members by recruitment month. A. Bars indicating

the number of households recruited each month into the study from which we obtained the household

transmission data used in our analyses, from March to November 2020. B. Equivalent panel showing the total

230 number of individuals within the households recruited each month.



232

233 Figure S6. Temporal changes in the generation time distribution for the mechanistic model. Violin plots

- 234 indicating posterior distributions of the mean generation time (A), standard deviation of generation times (B),
- and overall infectiousness parameter, β_0 (C), for the mechanistic model fitted to data from March-April (blue),
- 236 May-August (red) or September-November 2020 (orange).





239 Figure S7. Monthly changes in the generation time distribution from September-November 2020. Violin

240 plots indicating posterior distributions of the mean generation time (A), standard deviation of generation times

- 241 (B), and overall infectiousness parameter, β_0 (C), for the independent transmission and symptoms model fitted
- to data from September (blue), October (red) or November 2020 (orange).





Figure S8. Sensitivity of results to the functional forms of the generation time and incubation period

246 distributions for the independent transmission and symptoms model. A-C. Violin plots indicating posterior

247 distributions of the mean generation time (A), standard deviation of generation times (B), and overall

248 infectiousness parameter, β_0 (C), for the independent transmission and symptoms model, when the generation

time was assumed to follow either a lognormal (blue, as in the main text) or a gamma (red) distribution, and the

250 incubation period distribution followed a lognormal distribution (as in the main text). D-F. Equivalent panels to

251 A-C, instead comparing cases where the incubation period was assumed to follow either a lognormal

distribution (blue, as in the main text) or a gamma distribution with the same mean and standard deviation (red),

and the generation time followed a lognormal distribution (as in the main text).





256 Figure S9. Sensitivity of the results to the incubation period distribution. A-B. Uncertainty in the incubation 257 period distribution was accounted for by updating the parameters, μ_{inc} and σ_{inc} , of a lognormal incubation 258 period distribution (these parameters represent the mean and standard deviation of the natural logarithm of the 259 incubation period distribution, respectively) alongside unknown model parameters in the MCMC procedure. 260 Independent normal prior distributions (truncated at zero) consistent with the 95% confidence intervals obtained 261 in [2] were assumed for μ_{inc} (prior mean 1.63 log(day), standard deviation 0.061, 95% CrI 1.51-1.75; panel A) 262 and σ_{inc} (prior mean 0.5 log(day), standard deviation 0.026, 95% CrI 0.45-0.55; panel B). This incubation 263 period was used directly when evaluating the likelihood in the independent transmission and symptoms model. 264 In the mechanistic model, we assumed a gamma distributed incubation period with the same mean and standard 265 deviation as a lognormal distribution with parameters μ_{inc} and σ_{inc} . C-E. Violin plots indicating posterior 266 distributions of the mean generation time (C), standard deviation of generation times (D), and overall 267 infectiousness parameter, β_0 (E), for the independent transmission and symptoms model with either a fixed (as 268 in the main text; blue) or variable (i.e., accounting for uncertainty in μ_{inc} and σ_{inc} as described above; red) 269 incubation period distribution, and for the mechanistic model with a fixed (orange) or variable (purple) 270 incubation period distribution.









Figure S11. Sensitivity of the results to the relative infectiousness of entirely asymptomatic infected hosts.

285 Violin plots indicating posterior distributions of the mean generation time (A), standard deviation of generation

286 times (B), and overall infectiousness parameter, β_0 (C), for the independent transmission and symptoms model,

287 when the relative infectiousness of asymptomatic hosts (compared to a host who develops symptoms, at the

288 same time since infection) was $\alpha_A = 0.1$ (blue), $\alpha_A = 0.35$ (red) and $\alpha_A = 1.27$ (orange).

289





291 Figure S12. Sensitivity of the results to the exclusion of hosts with unknown infection status. A-C. Violin

292 plots indicating the posterior distributions of the mean generation time (A), standard deviation of generation

- 293 times (B), and overall infectiousness parameter, β_0 (C), for the independent transmission and symptoms model,
- when hosts with unknown infection status were assumed all uninfected (blue), excluded (red), or assumed all
- 295 infected (orange).

297 Supplementary Tables:

Parameter	Model	Interpretation	Value	Justification
α_A	Both	Relative	0.35	Taken from [3]
		infectiousness		(other values
		of entirely		considered in
		asymptomatic		sensitivity
		hosts		analyses)
Mean of natural	Independent	Parameter of	1.63 log(day)	Taken from [2]
logarithm of the	transmission	lognormal		(uncertainty in
incubation	and symptoms	incubation		this value
period		period		considered in
		distribution		sensitivity
				analyses)
Standard	Independent	Parameter of	0.50 log(day)	Taken from [2]
deviation of	transmission	lognormal		(uncertainty in
natural	and symptoms	incubation		this value
logarithm of the		period		considered in
incubation		distribution		sensitivity
period				analyses)
k _{inc}	Mechanistic	Shape	3.5	Consistent with
		parameter of		mean and
		gamma		standard
		incubation		deviation in [2]
		period		
		distribution		
$1/\gamma$	Mechanistic	Mean	5.8 days	Consistent with
		incubation		mean and
		period		standard
				deviation in [2]
k_I	Mechanistic	Shape	1	Assumed
		parameter of		
		(gamma)		
		symptomatic		
		infectious		
		period		
		distribution		

298

299 Table S1. Assumed (not fitted) parameter values used for the two models that we considered.

Parameter	Prior	Posterior mean (95% CrI)
Mean generation	Lognormal(1.6,0.35)	4.2 days
time	[prior median 5.0 days, 95%	(3.3-5.3 days)
	CI 2.5-9.8 days]	
Standard deviation	Lognormal(0.7,0.65)	4.9 days
of generation times	[prior median 2.0 days, 95%	(3.0-8.3 days)
	CI 0.6-7.2 days]	
Overall	Lognormal(0.7,0.8)	1.7
infectiousness	[prior median 2.0, 95% CI	(1.4-1.9)
parameter, β_0	0.4-9.7]	

- **Table S2.** Fitted parameters in the independent transmission and symptoms model, the prior distributions used,
- **302** and the posterior means and 95% credible intervals obtained.

Parameter	Prior	Posterior mean (95% CrI)
Ratio of mean durations of	Beta(2.1,2.1)	0.2
the latent (E) and incubation	[prior median 0.5, 95% CI	(0.03-0.5)
$(E+P)$ periods, k_E/k_{inc}	0.1-0.9]	
Mean symptomatic	Lognormal(1.6,0.8)	5.0 days
infectious (I) period, $1/\mu$	[prior median 5.0 days, 95%	(3.2-7.5 days)
	CI 1.0-23.8 days]	
Ratio of transmission rates	Lognormal(0,0.8)	3.1
in the P and I stages, α_P	[prior median 1.0, 95% CI	(1.2-6.9)
	0.2-4.8]	
Overall infectiousness	Lognormal(0.7,0.8)	1.8
parameter, β_0	[prior median 2.0, 95% CI	(1.5-2.1)
	0.4-9.7]	

Table S3. Fitted parameters in the mechanistic model, the prior distributions used, and the posterior means and

95% credible intervals obtained.

308 References:

- 309 [1] Hart WS, Maini PK, Thompson RN. High infectiousness immediately before COVID310 19 symptom onset highlights the importance of continued contact tracing. *eLife* 2021;
 311 10: e65534.
- 312 [2] McAloon C, Collins Á, Hunt K, et al. Incubation period of COVID-19: a rapid
 313 systematic review and meta-analysis of observational research. *BMJ Open* 2020; 10:
 314 e039652.
- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission
 potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living
 systematic review and meta-analysis. *PLOS Med* 2020; 17: e1003346.